ADMA BiologicsADMA -0.54%64 Quick Ratio is 3.93 as of Mar. 2026, which is 38% above its 10-year median of 2.85. GuruFocus rates ADMA with a GF Score™ of 64/100 and a GF Value™ of $18.04 (Significantly Undervalued). The stock has 2 warning signs investors should review. Among 1,408 Biotechnology companies, ADMA Biologics ranks better than 52.41% on this metric.
The quick ratio measures a company's ability to meet its short-term obligations with its most liquid assets. It is calculated as a company's Total Current Assets excludes Total Inventories divides by its Total Current Liabilities. ADMA Biologics's quick ratio for the quarter that ended in Mar. 2026 was 3.93.
ADMA Biologics has a quick ratio of 3.93. It generally indicates good short-term financial strength.
The historical rank and industry rank for ADMA Biologics's Quick Ratio or its related term are showing as below:
ADMA'
s Quick Ratio Range Over the Past 10 Years
Min: 0.8 Med: 2.85 Max: 8.87
Current: 3.93
During the past 13 years, ADMA Biologics's highest Quick Ratio was 8.87. The lowest was 0.80. And the median was 2.85.
ADMA's Quick Ratio is ranked better than 52.41% of 1408
companies
in the Biotechnology industry
Industry Median: 3.6
vs ADMA: 3.93
ADMA Biologics (NAS:ADMA) Quick Ratio Explanation
The quick ratio is more conservative than the Current Ratio because it excludes inventories from current assets. The ratio derives its name presumably from the fact that assets such as cash and marketable securities are quick sources of cash. Inventories generally take time to be converted into cash, and if they have to be sold quickly, the company may have to accept a lower price than book value of these inventories. As a result, they are justifiably excluded from assets that are ready sources of immediate cash.
In general, low or decreasing quick ratios generally suggest that a company is over-leveraged, struggling to maintain or grow sales, paying bills too quickly or collecting receivables too slowly. On the other hand, a high or increasing quick ratio generally indicates that a company is experiencing solid top-line growth, quickly converting receivables into cash, and easily able to cover its financial obligations. Such companies often have faster inventory turnover and cash conversion cycles.
The higher the quick ratio, the better the company's liquidity position.
ADMA Biologics Quick Ratio Related Terms
ADMA Biologics Quick Ratio Historical Data
* Premium members only.
The historical data trend for ADMA Biologics's Quick Ratio can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Biotechnology subindustry, ADMA Biologics's Quick Ratio, along with its competitors' market caps and Quick Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
ADMA Biologics Quick Ratio vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, ADMA Biologics's Quick Ratio distribution charts can be found below:
* The bar in red indicates where ADMA Biologics's Quick Ratio falls into.
The quick ratio measures a company's ability to meet its short-term obligations with its most liquid assets. For this reason, the ratio excludes inventories from current assets.
ADMA Biologics's Quick Ratio for the fiscal year that ended in Dec. 2025 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
ADMA Biologics (ADMA) has a Quick Ratio of 3.93 as of Mar. 2026. Quick ratio is the ratio of current assets less inventory to current liabilities. View historical data on ADMA Biologics and its competitors. This is 38% above median its historical median of 2.85. Over the past decade, ADMA Biologics' Quick Ratio has ranged from 0.80 to 8.87. According to the industry distribution chart, ADMA Biologics ranks #670 out of 1408 companies in the Biotechnology industry, placing it in the top 47.6%.
Is ADMA Biologics' Quick Ratio too high?
ADMA Biologics' current Quick Ratio of 3.93 is 38% above median its 10-year median of 2.85. Over the past 10 years, this metric has ranged from a low of 0.80 to a high of 8.87. The Biotechnology industry median Quick Ratio is 3.60. ADMA Biologics' value of 3.93 is 9.2% above this industry median. Based on the distribution chart, ADMA Biologics ranks #670 out of 1408 companies in the Biotechnology industry, which is above the industry midpoint. Overall, ADMA Biologics has a GF Score™ of 64/100 and is considered Significantly Undervalued, reflecting its overall financial health beyond just this single metric.
How does ADMA Biologics' Quick Ratio compare to ZLAB and HRMY?
According to the Biotechnology industry distribution chart, ADMA Biologics ranks #670 out of 1408 companies for Quick Ratio. This puts ADMA Biologics in the upper half of its industry. The industry median Quick Ratio is 3.60. ADMA Biologics' value of 3.93 is 9.2% above this benchmark. Historically, ADMA Biologics' own Quick Ratio has ranged from 0.80 to 8.87 over the past decade. While the company's 10-year median is 2.85 vs. the industry median of 3.60, ADMA Biologics has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Quick Ratio for a Biotechnology company?
The median Quick Ratio among Biotechnology companies is 3.60, based on 1,408 companies in the industry. Companies in the top quartile (top 25%) have a Quick Ratio significantly above this median, while those in the bottom quartile fall well below. However, Quick Ratio should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. ADMA Biologics's current Quick Ratio of 3.93 is 9.2% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Quick Ratio mean?
A high Quick Ratio can signal that a stock is expensive relative to its fundamentals. Quick ratio is the ratio of current assets less inventory to current liabilities. View historical data on ADMA Biologics and its competitors. For the Biotechnology industry, the median Quick Ratio is 3.60 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. ADMA Biologics's current Quick Ratio is 3.93, which is 38% above median its own 10-year median of 2.85. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is ADMA Biologics stock overvalued right now?
Based on GuruFocus' analysis, ADMA Biologics (ADMA) is currently considered Significantly Undervalued. The stock's GF Value™ is $18.04, compared to a current price of $9.16 — trading 49.2% below its estimated fair value. The current Quick Ratio is 3.93, which is 38% above median its 10-year median of 2.85 and 9.2% above the Biotechnology industry median of 3.60. ADMA Biologics' overall GF Score™ is 64/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Quick Ratio calculated?
Quick Ratio is calculated from a company's financial statements. For ADMA Biologics (ADMA), the current Quick Ratio is 3.93 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is ADMA Biologics (ADMA) Overvalued in 2026?
Based on GuruFocus' analysis, ADMA Biologics stock appears to be undervalued.
The current stock price of $9.16 is trading 49.2% below its estimated GF Value™ of $18.04.
GuruFocus considers ADMA Biologics to be Significantly Undervalued.
Key valuation signals for ADMA:
Quick Ratio: 3.93 (38% above median its 10-year median of 2.85)
GF Value™: $18.04 vs. price of $9.16 (49.2% below fair value)
Industry Position: 9.2% above the Biotechnology median (#670 of 1408)
No single metric tells the full story. See the ADMA stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
ADMA Biologics Inc is an end-to-end commercial biopharmaceutical company dedicated to manufacturing, marketing, and developing specialty plasma-derived biologics for the treatment of immunodeficient patients at risk for infection and others at risk for certain infectious diseases. The segments of the company are ADMA BioManufacturing, which generates maximum revenue, Plasma Collection Centres, and the corporate segment. The company sells plasma-derived intermediate fractions to certain customers, which are generated as part of its FDA-approved manufacturing process for IG and IVIG products. It also provides laboratory contracting services to certain customers and anticipates providing contract filling, labeling & packing services. The company derives maximum revenue from the United States.
64GF Score
Get the complete analysis for ADMA
Quick Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
ADMA has been successfully added to your 
